NASDAQ:SAGE - SAGE Therapeutics Stock Price, Price Target & More

$145.49 -2.52 (-1.70 %)
(As of 04/24/2018 08:42 AM ET)
Previous Close$148.01
Today's Range$142.15 - $151.65
52-Week Range$59.57 - $195.97
Volume633,000 shs
Average Volume576,827 shs
Market Capitalization$6.78 billion
P/E Ratio-20.52
Dividend YieldN/A
Beta3.03

About SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics logoSage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which has completed Phase II clinical trials for the treatment of PPD, major depressive disorders, bipolar depression, Parkinson's disease, and sleep disorders; and SAGE-718, an oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of depression, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, Huntington's disease, and neuropathic pain. In addition, its product pipeline comprises SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and product pipeline that are in preclinical stage includes SAGE-689 and SAGE-105 novel GABAA receptor modulators The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SAGE
CUSIPN/A
Phone617-299-8380

Debt

Debt-to-Equity RatioN/A
Current Ratio10.11%
Quick Ratio10.11%

Price-To-Earnings

Trailing P/E Ratio-20.52
Forward P/E Ratio-17.51
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$11.58 per share
Price / Book12.56

Profitability

EPS (Most Recent Fiscal Year)($7.09)
Net Income$-270,120,000.00
Net MarginsN/A
Return on Equity-86.14%
Return on Assets-75.79%

Miscellaneous

Employees257
Outstanding Shares45,780,000

How to Become a New Pot Stock Millionaire

SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

What is SAGE Therapeutics' stock symbol?

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How were SAGE Therapeutics' earnings last quarter?

SAGE Therapeutics Inc (NASDAQ:SAGE) released its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.98) by $0.23. During the same period in the previous year, the firm posted ($1.50) EPS. View SAGE Therapeutics' Earnings History.

What price target have analysts set for SAGE?

15 equities research analysts have issued twelve-month price targets for SAGE Therapeutics' stock. Their predictions range from $86.00 to $280.00. On average, they expect SAGE Therapeutics' stock price to reach $185.20 in the next twelve months. View Analyst Ratings for SAGE Therapeutics.

Who are some of SAGE Therapeutics' key competitors?

Who are SAGE Therapeutics' key executives?

SAGE Therapeutics' management team includes the folowing people:
  • Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 65)
  • Ms. Kimi E. Iguchi, CFO & Principal Accounting Officer (Age 56)
  • Dr. Albert J. Robichaud Ph.D., Chief Scientific Officer (Age 57)
  • Ms. Anne Marie Cook Esq., Sr. VP, Gen. Counsel & Sec. (Age 56)
  • Dr. Stephen J. Kanes M.D., Ph.D., Chief Medical Officer (Age 53)

Has SAGE Therapeutics been receiving favorable news coverage?

Press coverage about SAGE stock has been trending somewhat positive recently, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SAGE Therapeutics earned a media sentiment score of 0.08 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.25 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of SAGE Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SAGE Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $145.49.

How big of a company is SAGE Therapeutics?

SAGE Therapeutics has a market capitalization of $6.78 billion. The biopharmaceutical company earns $-270,120,000.00 in net income (profit) each year or ($7.09) on an earnings per share basis. SAGE Therapeutics employs 257 workers across the globe.

How can I contact SAGE Therapeutics?

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]


MarketBeat Community Rating for SAGE Therapeutics (SAGE)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  379 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  538
MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe SAGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

SAGE Therapeutics (NASDAQ:SAGE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
15 Wall Street analysts have issued ratings and price targets for SAGE Therapeutics in the last 12 months. Their average twelve-month price target is $185.20, suggesting that the stock has a possible upside of 27.29%. The high price target for SAGE is $280.00 and the low price target for SAGE is $86.00. There are currently 1 sell rating, 1 hold rating and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.793.00
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
2 Strong Buy Rating(s)
Consensus Price Target: $185.20$183.9333$171.2143$86.7857
Price Target Upside: 27.29% upside10.50% upside0.12% upside37.93% upside

SAGE Therapeutics (NASDAQ:SAGE) Consensus Price Target History

Price Target History for SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics (NASDAQ:SAGE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2018Canaccord GenuityReiterated RatingBuy -> Buy$210.00HighView Rating Details
3/20/2018CowenReiterated RatingBuy$202.00LowView Rating Details
2/28/2018SunTrust BanksBoost Price TargetBuy$203.00LowView Rating Details
2/26/2018Morgan StanleyInitiated CoverageOverweight -> Overweight$225.00LowView Rating Details
2/23/2018Needham & Company LLCReiterated RatingBuy$193.00LowView Rating Details
1/10/2018JPMorgan ChaseReiterated RatingBuyHighView Rating Details
12/8/2017Stifel NicolausReiterated RatingBuy$198.00LowView Rating Details
12/7/2017Raymond JamesReiterated RatingBuy$206.00HighView Rating Details
12/7/2017Leerink SwannBoost Price Target$123.00 -> $246.00HighView Rating Details
12/7/2017BMO Capital MarketsReiterated RatingOutperform$203.00HighView Rating Details
12/7/2017Royal Bank of CanadaBoost Price TargetOutperform -> Sell$137.00 -> $280.00HighView Rating Details
11/16/2017Bank of AmericaLower Price TargetBuy$103.00 -> $101.00N/AView Rating Details
11/10/2017Chardan CapitalUpgradeNeutral -> Buy$60.00 -> $140.00N/AView Rating Details
10/6/2017Goldman SachsReiterated RatingBuy -> Buy$87.00N/AView Rating Details
8/4/2017HC WainwrightBoost Price TargetNeutral$86.00HighView Rating Details
12/14/2016UBSUpgradeOutperform -> Strong-BuyN/AView Rating Details
7/15/2016William BlairReiterated RatingOutperform$75.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

SAGE Therapeutics (NASDAQ:SAGE) Earnings History and Estimates Chart

Earnings by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics (NASDAQ:SAGE) Earnings Estimates

2018 EPS Consensus Estimate: ($7.59)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.76)($1.75)($1.76)
Q2 20182($1.87)($1.75)($1.81)
Q3 20183($2.02)($1.91)($1.95)
Q4 20183($2.16)($1.95)($2.07)

SAGE Therapeutics (NASDAQ SAGE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018Q4 2017($1.9810)($1.75)ViewN/AView Earnings Details
11/2/2017Q3 2017($1.9830)($1.97)ViewN/AView Earnings Details
8/3/2017Q2 2017($1.63)($1.88)ViewListenView Earnings Details
5/9/2017Q1 2017($1.6080)($1.52)ViewListenView Earnings Details
2/23/2017Q4 2016($1.17)($1.50)ViewN/AView Earnings Details
11/3/2016Q316($1.10)($1.15)ViewN/AView Earnings Details
8/9/2016Q216($1.02)($1.08)ViewN/AView Earnings Details
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details
11/5/2015Q3 2015($0.85)($0.84)ViewN/AView Earnings Details
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

SAGE Therapeutics (NASDAQ:SAGE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

SAGE Therapeutics (NASDAQ SAGE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 96.35%
Insider Trading History for SAGE Therapeutics (NASDAQ:SAGE)
Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics (NASDAQ SAGE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2018Kevin P StarrDirectorSell59,000$168.85$9,962,150.00326,817View SEC Filing  
3/6/2018Steven M PaulDirectorSell58,139$172.00$9,999,908.00632,712View SEC Filing  
1/10/2018Stephen KanesInsiderSell44,000$177.18$7,795,920.0046,348View SEC Filing  
12/21/2017Jeffrey M JonasCEOSell210,247$157.45$33,103,390.15211,473View SEC Filing  
12/14/2017Albert RobichaudInsiderSell60,000$159.43$9,565,800.00152,759View SEC Filing  
1/13/2017Kimi IguchiCFOSell10,000$53.92$539,200.00View SEC Filing  
11/17/2016Kimi IguchiCFOSell4,000$51.77$207,080.0075,739View SEC Filing  
11/11/2016Kimi IguchiCFOSell1,500$50.59$75,885.0079,739View SEC Filing  
9/7/2016Kimi IguchiCFOSell2,500$40.93$102,325.0081,239View SEC Filing  
7/12/2016Albert RobichaudInsiderSell22,000$40.00$880,000.00140,222View SEC Filing  
7/12/2016Kimi IguchiCFOSell5,000$49.55$247,750.0083,739View SEC Filing  
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.0065,227View SEC Filing  
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.0025,948View SEC Filing  
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00162,222View SEC Filing  
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.0046,948View SEC Filing  
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.0084,563View SEC Filing  
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00683,650View SEC Filing  
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.0031,948View SEC Filing  
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

SAGE Therapeutics (NASDAQ SAGE) News Headlines

Source:
DateHeadline
Sage files U.S. marketing application for PPD med brexanolone; shares up 1% premarketSage files U.S. marketing application for PPD med brexanolone; shares up 1% premarket
seekingalpha.com - April 23 at 8:38 AM
Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum DepressionSage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression
finance.yahoo.com - April 23 at 8:38 AM
Sage Therapeutics asks FDA to approve lead drug for postpartum depressionSage Therapeutics asks FDA to approve lead drug for postpartum depression
finance.yahoo.com - April 23 at 8:38 AM
Sage Therapeutics down 7% on Biogen/Ionis dealSage Therapeutics down 7% on Biogen/Ionis deal
seekingalpha.com - April 20 at 4:57 PM
Why Stanley Black & Decker, ManpowerGroup, and Sage Therapeutics Slumped TodayWhy Stanley Black & Decker, ManpowerGroup, and Sage Therapeutics Slumped Today
finance.yahoo.com - April 20 at 4:57 PM
Kevin P. Starr Sells 59,000 Shares of SAGE Therapeutics Inc (SAGE) StockKevin P. Starr Sells 59,000 Shares of SAGE Therapeutics Inc (SAGE) Stock
www.americanbankingnews.com - April 19 at 7:18 PM
Sage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical MeetingsSage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings
finance.yahoo.com - April 17 at 5:26 PM
SAGE Therapeutics (SAGE) Downgraded by BidaskClubSAGE Therapeutics (SAGE) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 9:17 PM
 Brokerages Anticipate SAGE Therapeutics Inc (SAGE) to Post -$1.85 EPS Brokerages Anticipate SAGE Therapeutics Inc (SAGE) to Post -$1.85 EPS
www.americanbankingnews.com - April 14 at 3:11 PM
Sage takeover rumors unfoundedSage takeover rumors unfounded
seekingalpha.com - April 10 at 5:03 PM
Noteworthy Tuesday Option Activity: DDS, COST, SAGENoteworthy Tuesday Option Activity: DDS, COST, SAGE
www.nasdaq.com - April 10 at 5:03 PM
SAGE Therapeutics (SAGE) Rating Lowered to Sell at BidaskClubSAGE Therapeutics (SAGE) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM
SAGE Therapeutics Inc (SAGE) Receives Average Recommendation of "Buy" from BrokeragesSAGE Therapeutics Inc (SAGE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 4 at 3:22 AM
ValuEngine Upgrades SAGE Therapeutics (SAGE) to "Buy"ValuEngine Upgrades SAGE Therapeutics (SAGE) to "Buy"
www.americanbankingnews.com - April 3 at 12:30 AM
SAGE Therapeutics Inc (SAGE) Expected to Post Earnings of -$1.85 Per ShareSAGE Therapeutics Inc (SAGE) Expected to Post Earnings of -$1.85 Per Share
www.americanbankingnews.com - March 28 at 5:24 PM
Sage CEO on post-partum depression, innovation for the co...Sage CEO on post-partum depression, innovation for the co...
finance.yahoo.com - March 28 at 4:55 PM
Sage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug ‘fairly’Sage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug ‘fairly’
finance.yahoo.com - March 28 at 4:55 PM
Canaccord Genuity Analysts Give SAGE Therapeutics (SAGE) a $210.00 Price TargetCanaccord Genuity Analysts Give SAGE Therapeutics (SAGE) a $210.00 Price Target
www.americanbankingnews.com - March 26 at 8:37 AM
SAGE Therapeutics (SAGE) Earns "Buy" Rating from CowenSAGE Therapeutics (SAGE) Earns "Buy" Rating from Cowen
www.americanbankingnews.com - March 20 at 9:22 PM
Corbus Pharmaceuticals (CRBP) vs. SAGE Therapeutics (SAGE) Head-To-Head ContrastCorbus Pharmaceuticals (CRBP) vs. SAGE Therapeutics (SAGE) Head-To-Head Contrast
www.americanbankingnews.com - March 18 at 5:20 PM
Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage ...Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage ...
www.prnewswire.com - March 16 at 8:58 AM
Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra OncologyPre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra Oncology
www.bizjournals.com - March 16 at 8:58 AM
See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.
finance.yahoo.com - March 15 at 5:35 PM
Analyst Has 4 Favorite Biotechnology Stocks to Buy NowAnalyst Has 4 Favorite Biotechnology Stocks to Buy Now
www.msn.com - March 15 at 5:35 PM
SAGE Therapeutics (SAGE) Lifted to "Hold" at BidaskClubSAGE Therapeutics (SAGE) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - March 11 at 3:52 PM
SAGE Therapeutics Inc (SAGE) Receives Average Recommendation of "Buy" from AnalystsSAGE Therapeutics Inc (SAGE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 10 at 3:54 AM
Insider Selling: SAGE Therapeutics Inc (SAGE) Director Sells 58,139 Shares of StockInsider Selling: SAGE Therapeutics Inc (SAGE) Director Sells 58,139 Shares of Stock
www.americanbankingnews.com - March 8 at 6:12 PM
Here's Why Marinus Pharmaceuticals Dropped as Much as 17.7% TodayHere's Why Marinus Pharmaceuticals Dropped as Much as 17.7% Today
finance.yahoo.com - March 6 at 5:17 PM
Biotech Jumps After Rival Pushes Back Depression Drug TestsBiotech Jumps After Rival Pushes Back Depression Drug Tests
finance.yahoo.com - March 6 at 5:17 PM
17,200 Shares in SAGE Therapeutics Inc (SAGE) Acquired by Sectoral Asset Management Inc17,200 Shares in SAGE Therapeutics Inc (SAGE) Acquired by Sectoral Asset Management Inc
www.americanbankingnews.com - March 6 at 2:11 PM
American International Group Inc. Acquires 2,309 Shares of SAGE Therapeutics Inc (SAGE)American International Group Inc. Acquires 2,309 Shares of SAGE Therapeutics Inc (SAGE)
www.americanbankingnews.com - March 6 at 4:22 AM
SAGE Therapeutics Inc (SAGE) Stake Lessened by UBS Asset Management Americas Inc.SAGE Therapeutics Inc (SAGE) Stake Lessened by UBS Asset Management Americas Inc.
www.americanbankingnews.com - March 2 at 7:50 PM
SAGE Therapeutics Inc (SAGE) Shares Bought by State of Wisconsin Investment BoardSAGE Therapeutics Inc (SAGE) Shares Bought by State of Wisconsin Investment Board
www.americanbankingnews.com - March 1 at 6:10 PM
Analysts Offer Predictions for SAGE Therapeutics Incs Q1 2018 Earnings (SAGE)Analysts Offer Predictions for SAGE Therapeutics Inc's Q1 2018 Earnings (SAGE)
www.americanbankingnews.com - March 1 at 7:14 AM
Analysts Issue Forecasts for SAGE Therapeutics Incs FY2022 Earnings (SAGE)Analysts Issue Forecasts for SAGE Therapeutics Inc's FY2022 Earnings (SAGE)
www.americanbankingnews.com - February 28 at 4:48 PM
SAGE Therapeutics (SAGE) PT Raised to $203.00SAGE Therapeutics (SAGE) PT Raised to $203.00
www.americanbankingnews.com - February 28 at 4:44 PM
EAM Investors LLC Invests $3.28 Million in SAGE Therapeutics Inc (SAGE) StockEAM Investors LLC Invests $3.28 Million in SAGE Therapeutics Inc (SAGE) Stock
www.americanbankingnews.com - February 28 at 1:56 PM
SAGE Therapeutics Inc (SAGE) Position Increased by BlackRock Inc.SAGE Therapeutics Inc (SAGE) Position Increased by BlackRock Inc.
www.americanbankingnews.com - February 28 at 5:16 AM
SAGE Therapeutics Inc (SAGE) Shares Bought by California Public Employees Retirement SystemSAGE Therapeutics Inc (SAGE) Shares Bought by California Public Employees Retirement System
www.americanbankingnews.com - February 27 at 5:20 AM
Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A BuyMorgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy
finance.yahoo.com - February 26 at 5:22 PM
SAGE Therapeutics (SAGE) Research Coverage Started at Morgan StanleySAGE Therapeutics (SAGE) Research Coverage Started at Morgan Stanley
www.americanbankingnews.com - February 26 at 2:35 PM
SAGE Therapeutics Inc Forecasted to Earn Q3 2018 Earnings of ($1.92) Per Share (SAGE)SAGE Therapeutics Inc Forecasted to Earn Q3 2018 Earnings of ($1.92) Per Share (SAGE)
www.americanbankingnews.com - February 26 at 4:37 AM
Analyzing Oncobiologics (ONS) and SAGE Therapeutics (SAGE)Analyzing Oncobiologics (ONS) and SAGE Therapeutics (SAGE)
www.americanbankingnews.com - February 25 at 9:24 AM
Carillon Tower Advisers Inc. Acquires Shares of 451,097 SAGE Therapeutics Inc (SAGE)Carillon Tower Advisers Inc. Acquires Shares of 451,097 SAGE Therapeutics Inc (SAGE)
www.americanbankingnews.com - February 25 at 4:58 AM
Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Pipeline Update - Business Wire (press release)Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Pipeline Update - Business Wire (press release)
www.businesswire.com - February 24 at 8:44 AM
SAGE Therapeutics (SAGE) Buy Rating Reaffirmed at Needham & Company LLCSAGE Therapeutics' (SAGE) Buy Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - February 23 at 5:51 PM
Zacks: Brokerages Anticipate SAGE Therapeutics Inc (SAGE) Will Announce Earnings of -$2.04 Per ShareZacks: Brokerages Anticipate SAGE Therapeutics Inc (SAGE) Will Announce Earnings of -$2.04 Per Share
www.americanbankingnews.com - February 22 at 5:20 PM
Cellular Dynamics International (ICEL) & SAGE Therapeutics (SAGE) Financial SurveyCellular Dynamics International (ICEL) & SAGE Therapeutics (SAGE) Financial Survey
www.americanbankingnews.com - February 22 at 1:18 PM
SAGE Therapeutics (SAGE) Issues Quarterly  Earnings ResultsSAGE Therapeutics (SAGE) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 22 at 12:32 PM
Form 10-K Sage Therapeutics, Inc. For: Dec 31Form 10-K Sage Therapeutics, Inc. For: Dec 31
www.streetinsider.com - February 22 at 8:48 AM

SEC Filings

SAGE Therapeutics (NASDAQ:SAGE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

SAGE Therapeutics (NASDAQ:SAGE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

SAGE Therapeutics (NASDAQ SAGE) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.